Drug Trial Radar · NCT06859099
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
300
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Oct 3, 2029
Study completion Oct 3, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant will be up to approximately 4 years, including posttreatment follow-up. The treatment duration will be up to approximately 3 years. A participant who discontinues riliprubart treatment at any time during the study will be followed for safety for a minimum of 55 weeks after the last dose of riliprubart received.
Conditions
- Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Riliprubart Prefilled Pen (PFP)Drug
Pharmaceutical form: Solution Route of administration: Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study periodTime frame: Up to End of Study (approx. 4 years)
Locations
63 sites in 24 countries. Site status is shown where the registry gives one.
Alabama Neurology Associates- Site Number : 8400019
Homewood, Alabama
Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014
Scottsdale, Arizona
University of Kansas Medical Center- Site Number : 8400010
Kansas City, Kansas
Columbia University Irving Medical Center- Site Number : 8400003
New York, New York
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022
Philadelphia, Pennsylvania
Investigational Site Number : 0320003
Buenos Aires, Argentina
PSEG Centro de Pesquisa Clínica- Site Number : 0760009
São Paulo, Brazil
L2IP - Instituto de Pesquisas Clínicas- Site Number : 0760006
Brasília, Federal District, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760004
Ribeirão Preto, São Paulo, Brazil
Investigational Site Number : 1000002
Blagoevgrad, Bulgaria
Investigational Site Number : 1240001
Gatineau, Quebec, Canada
Investigational Site Number : 1240002
Québec, Quebec, Canada
Investigational Site Number : 1520003
Lo Barnechea, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Puente Alto, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1560013
Beijing, China
Investigational Site Number : 1560005
Beijing, China
Investigational Site Number : 1560009
Changsha, China
Investigational Site Number : 1560011
Chengdu, China
Investigational Site Number : 1560002
Fuzhou, China
Investigational Site Number : 1560012
Guangzhou, China
Investigational Site Number : 1560014
Hangzhou, China
Investigational Site Number : 1560001
Shanghai, China
Investigational Site Number : 1560003
Wuhan, China
Investigational Site Number : 1560006
Wuhan, China
Investigational Site Number : 1560004
Xi'an, China
Investigational Site Number : 2030004
Brno, Czechia
Investigational Site Number : 2030001
Prague, Czechia
Investigational Site Number : 2080002
Aarhus, Denmark
Investigational Site Number : 2080001
Copenhagen, Denmark
Investigational Site Number : 2500007
Bordeaux, France
Investigational Site Number : 2500001
Le Kremlin-Bicêtre, France
Investigational Site Number : 2500002
Marseille, France
Investigational Site Number : 2500005
Montpellier, France
Investigational Site Number : 2500004
Paris, France
Investigational Site Number : 2760002
Göttingen, Germany
Investigational Site Number : 2760003
Münster, Germany
Investigational Site Number : 2760004
Tübingen, Germany
Investigational Site Number : 3800005
Pavia, Italy
Investigational Site Number : 3800007
Pisa, Italy
Investigational Site Number : 3800003
Genoa, Genova, Italy
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.